T2 Biosystems Inc.

07/19/2024 | Press release | Distributed by Public on 07/19/2024 14:17

Material Event Form 8 K

Item 8.01

Other Events

As previously disclosed, on March 31, 2021, the Company entered into an Equity Distribution Agreement (the "Equity Distribution Agreement") with Canaccord Genuity LLC ("Canaccord") to sell shares of the Company's common stock, from time to time, through an "at the market" equity offering program under which Canaccord acted as sales agent.

On July 19, 2024, the Equity Distribution Agreement was terminated pursuant to the terms therein. The Company is not subject to any termination penalties related to the termination of the Equity Distribution Agreement.

A copy of the Equity Distribution Agreement was filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3filed with the Securities and Exchange Commission on March 31, 2021 (the "2021 S-3").The description of the Equity Distribution Agreement contained in this Current Report on Form 8-Kdoes not purport to be complete and is qualified in its entirety by reference to the copy of the Equity Distribution Agreement filed as Exhibit 1.2 to the 2021 S-3.